to determine the magnitudes of cost drivers affected by new treatments. METHODS: A Markov model was built using TreeAge Pro Healthcare and parameterized to replicate the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) trial. The model reports results at 30 days, then every six-months over three-years for clopidogrel plus aspirin vs. a hypothetical alternative. Reductions in risk for five events are analyzed: myocardial infarction (MI), initial and subsequent percutaneous coronary intervention (PCI), refractory ischemia, and stroke. Modeled risks and costs of coronary bypass surgery and bleeding complication are not modified. Resulting states include: no event, post each event type, various cardiac deaths, and non-cardiac death. RESULTS: The effects on costs of reducing relative risks of each event (and all five together) by 10% and 20% are evaluated. Cost offsets at one and three-years are highest for initial PCI ($239, $724; 2.0%, 2.8% of total costs for time period) for a 20% six-month risk reduction. All other one-year offsets are less than 1.0%. Ten percent reductions produce nearly half the cost savings. Total savings for a 20% reduction in all five events are ($493, $1530; 4.1%, 5 .8%) at one and three-years. If, instead of reducing risks after the initial 30-day period, a 20% reduction in 30-day risk of PTCA is modeled, then costs decrease by $389, $480, and $616 at 30 days, one and three-years, respectively. CONCLU-SIONS: In this model, initial PCI influences cost more than MI, refractory ischemia, subsequent PCI, or stroke, but all are clinically important. Knowing the relationship between event costs and risk reductions can help estimate the potential cost impact of new treatments.
CARDIOVASCULAR DISEASE-Angioplasty PCV6

LONG-TERM COST-EFFECTIVENESS OF EARLY AND SUSTAINED DUAL ORAL ANTIPLATELET THERAPY WITH CLOPIDOGREL FOLLOWING PERCUTANEOUS CORONARY INTERVENTION (CREDO TRIAL): A FOUR-EUROPEAN COUNTRY ANALYSIS
Weintraub WS 1 , Bouin O 2 ,Veledar E 1 , Gabriel S 2 1 Emory University, Atlanta, GA, USA; 2 Sanofi-Aventis, Bagneux, France OBJECTIVES: The Clopidogrel for the Reduction of Events During Observation (CREDO) trial showed that clopidogrel loading prior to percutaneous coronary intervention (PCI) with one-year treatment after PCI reduced the combined risk of death, myocardial infarction (MI) or stroke. The purpose of this study was to evaluate the economic impact of clopidogrel based on CREDO in Switzerland, Belgium, Italy, and France. METHODS: We used clinical outcomes and resource use from CREDO combined with external survival data to assess the long-term costeffectiveness of clopidogrel. A total of 2116 patients with coronary artery disease were randomized to clopidogrel loading before PCI plus one year therapy (n = 1053) vs. 28 days clopidogrel followed by placebo (n = 1063). All patients received clopidogrel day zero to 28. In all, 89 (8.45%) patients in the treatment arm and 122 (11.48%) in the placebo group had an event (RRR 26.9%, 95% CI 3.9%-44.4%). Hospitalizations were assigned a Diagnostic Related Group (DRG) through a DRG grouper. Unit costs were developed in each country and applied to all patients of the CREDO study. Lost life expectancy associated with death, MI and stoke was estimated from Saskatchewan data and discounted 3%. Cost effectiveness was expressed as the cost per event avoided and as cost per Life year saved (LYS). RESULTS: The cost effectiveness of one year use of clopidogrel in addition to a clopidogrel loading strategy prior to PCI vs. placebo ranges from 15,765€ to 26,074€/event prevented. The cost per LYS is 2483€/LYS in Belgium, 2502€/LYS in France; 2552€/LYS in Italy; 2659€/LYS in Switzerland based on Saskatchewan projection. CONCLU-SION: Clopidogrel used prior to PCI and for one year thereafter is a cost effective strategy. Consistent results are found in the four countries studied.
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PCV7 HEALTH CARE RESOURCE UTILIZATION AND COST OF ATRIAL FLUTTER PATIENTS
Pelletier E 1 , Reyes CM 1 , Hernandez J 1 , Lee BK 2 1 Boston Scientific Corporation, San Jose, CA, USA; 2 University of California San Francisco, San Francisco, CA, USA OBJECTIVE: The objective of the study was to analyze annual health resource utilization and costs of patients with atrial flutter. While the majority of atrial flutter research has focused on various pharmacologic, cardioversion, and catheter ablation treatment options, the costs associated with treating atrial flutter patients have not been previously reported. METHODS: All patients receiving a diagnosis of atrial flutter (ICD-9 427.32) between January 1, and December 31, 2002 were identified from a nationally representative private payer database (IHCIS, Waltham, MA). Patients <18 years of age or not continuously enrolled in a health plan for one year following the atrial flutter diagnosis were removed from the analysis. Total one-year health resource use and costs, including hospital inpatient, outpatient, professional, ancillary, and pharmacy services, were measured from a third-party payer perspective. RESULTS: The study included 4945 patients with an atrial flutter diagnosis. The average age was 62 years; 65% were male. The top co-morbid conditions were atrial fibrillation (72.3%), hypertension (55%), and neoplasms (27%). Average total one-year medical costs for atrial flutter patients were $25,652 +/-$44,814, of which inpatient hospitalizations comprised almost 50% of the total cost. Over half of patients were hospitalized with mean length of stay of 6.78 +/-20.73 days, 83% had at least one outpatient visit, while almost all patients had a physician visit and 71% required at least one pharmacy visit during the one-year follow-up.
